Phosphoinositide 3-kinase alpha – RAS interaction interface (PI3Kα-RAS interface)

The Phosphoinositide 3-kinase alpha (PI3Kα) – RAS interaction interface is a specialized protein-protein interaction site where the Ras-binding domain (RBD) of the p110α catalytic subunit (encoded by the PIK3CA gene) physically associates with activated, GTP-bound RAS GTPases, including KRAS, HRAS, and NRAS (Gupta et al., 2007; UniProt P42336). This interaction is a fundamental step in the canonical growth factor signaling pathway, as it facilitates the recruitment of PI3Kα from the cytosol to the plasma membrane, where it can access its lipid substrate, phosphatidylinositol 4,5-bisphosphate (PIP2) (Castellano & Downward, 2011). The resulting production of PIP3 triggers the activation of the AKT/mTOR signaling axis, which governs essential cellular processes such as proliferation, survival, and glucose metabolism. In the context of oncology, this interface is particularly significant because many aggressive cancers are driven by oncogenic RAS mutations that lead to constitutive PI3K activation through this specific contact point (Fritsch et al., 2013). Therapeutic strategies targeting the PI3Kα-RAS interface, such as the use of RAS-mimetics like rigosertib, aim to selectively decouple RAS signaling from the PI3K pathway without inhibiting the basal kinase activity of PI3Kα (Athuluri-Divakar et al., 2016). This approach is designed to provide a more precise intervention for RAS-mutant tumors while potentially avoiding the systemic metabolic side effects, such as severe hyperglycemia, that are frequently observed with traditional ATP-competitive PI3K inhibitors.

Other names

p110α-RAS binding domainPIK3CA-RAS interfacePI3K-RAS interaction siteRAS-binding domain of p110αPhosphoinositide 3-kinase catalytic subunit alpha – RAS interaction interface

The mechanism of action involves the disruption of the physical association between the Ras-binding domain (RBD) of the PI3Kα catalytic subunit (p110α) and the activated, GTP-bound form of RAS proteins (KRAS, HRAS, NRAS) (Athuluri-Divakar et al., 2016). By competitively or allosterically blocking this protein-protein interaction, these agents prevent the recruitment of PI3Kα to the plasma membrane, thereby inhibiting the RAS-dependent activation of the PI3K/AKT/mTOR signaling pathway (Gupta et al., 2007).